-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
3 Stocks Under $3 Insiders Are Aggressively Buying
3 Stocks Under $3 Insiders Are Aggressively Buying
US crude oil futures traded lower on Monday. Investors, meanwhile, focused on some notable insider trades.
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
Rubius Therapeutics
- The Trade: Rubius Therapeutics, Inc. (NASDAQ:RUBY) Director David Epstein acquired a total of 30,000 shares at an average price of $1.44. To acquire these shares, it cost $43.33 thousand.
- What's Happening: Rubius Therapeutics recently announced updated data from the ongoing monotherapy Phase 1 arm of the Phase 1/2 trial of RTX-240 in advanced solid tumors.
- What Rubius Therapeutics Does: Rubius Therapeutics Inc develops red cell therapeutics (RCTs) for the treatment of patients with rare diseases, cancer, and autoimmune diseases.
Adverum Biotechnologies
- The Trade: Adverum Biotechnologies, Inc. (NASDAQ:ADVM) CEO, President and Director Laurent Fischer acquired a total of 25,000 shares at an average price of $1.11. The insider spent around $27.8 thousand to buy those shares.
- What's Happening: Adverum Biotechnologies recently received feedback via a Type C meeting written response from the FDA regarding its planned Phase 2 trial of ADVM-022 in wet age-related macular degeneration (wet AMD).
- What Adverum Biotechnologies Does: Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company.
Also check this: Insiders Buy More Than $15M Of 3 Stocks
Don't forget to check out our premarket coverage here .
Anixa Biosciences
- The Trade: Anixa Biosciences, Inc. (NASDAQ:ANIX) President Michael Catelani acquired a total of 5,500 shares at an average price of $2.66. To acquire these shares, it cost around $14.63 thousand.
- What's Happening: Anixa Biosciences, last month, announced the initiation of its ovarian cancer CAR-T Phase 1 trial at Moffitt Cancer Center.
- What Anixa Biosciences Does: Anixa Biosciences Inc, a cancer-focused biotechnology company, is engaged in harnessing the body's immune system in the fight against cancer.
US crude oil futures traded lower on Monday. Investors, meanwhile, focused on some notable insider trades.
美国原油期货周一走低。与此同时,投资者关注的是一些值得注意的内幕交易。
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
当内部人士买卖股票时,这表明了他们对公司前景的信心或担忧。对细价股感兴趣的投资者和交易员可以在他们的整体投资或交易决策中考虑这一因素。
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
以下是最近几笔值得注意的细价股内幕交易。欲了解更多信息,请查看Benzinga的内幕交易平台。
Rubius Therapeutics
Rubius治疗公司
- The Trade: Rubius Therapeutics, Inc. (NASDAQ:RUBY) Director David Epstein acquired a total of 30,000 shares at an average price of $1.44. To acquire these shares, it cost $43.33 thousand.
- What's Happening: Rubius Therapeutics recently announced updated data from the ongoing monotherapy Phase 1 arm of the Phase 1/2 trial of RTX-240 in advanced solid tumors.
- What Rubius Therapeutics Does: Rubius Therapeutics Inc develops red cell therapeutics (RCTs) for the treatment of patients with rare diseases, cancer, and autoimmune diseases.
- 行业: Rubius治疗公司纳斯达克(股票代码:RUBY)董事大卫·爱泼斯坦以1.44美元的平均价格收购了总计30,000股新浪微博。收购这些股份,花费了433.3万美元。
- 正在发生的事情:Rubius治疗公司最近宣布了正在进行的RTX-240治疗晚期实体肿瘤1/2期试验的1期单一疗法的最新数据。
- Rubius Treateutics的作用:Rubius治疗公司开发红细胞疗法(RCT),用于治疗罕见疾病、癌症和自身免疫性疾病的患者。
Adverum Biotechnologies
Adverum生物技术公司
- The Trade: Adverum Biotechnologies, Inc. (NASDAQ:ADVM) CEO, President and Director Laurent Fischer acquired a total of 25,000 shares at an average price of $1.11. The insider spent around $27.8 thousand to buy those shares.
- What's Happening: Adverum Biotechnologies recently received feedback via a Type C meeting written response from the FDA regarding its planned Phase 2 trial of ADVM-022 in wet age-related macular degeneration (wet AMD).
- What Adverum Biotechnologies Does: Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company.
- 《贸易》: Adverum生物技术公司纳斯达克(Sequoia Capital:ADVM)首席执行官兼总裁兼董事总裁费希尔以1.11美元的平均价格收购了总计25,000股董事股票。这位内部人士花了大约278千美元购买了这些股票。
- 发生了什么事?:Adverum生物技术公司最近通过一次C型会议收到了FDA关于其计划中的ADVM-022治疗湿性老年性黄斑变性(湿性AMD)的第二阶段试验的书面反馈。
- Adverum BioTechnologies做了什么:Adverum BioTechnologies Inc.是一家总部位于美国的临床阶段基因治疗公司。
Also check this: Insiders Buy More Than $15M Of 3 Stocks
还可以查一下:内部人士购买了3只股票,价值超过1500万美元
Don't forget to check out our premarket coverage here .
别忘了在这里查看我们的售前报道。
Anixa Biosciences
Anixa生物科学
- The Trade: Anixa Biosciences, Inc. (NASDAQ:ANIX) President Michael Catelani acquired a total of 5,500 shares at an average price of $2.66. To acquire these shares, it cost around $14.63 thousand.
- What's Happening: Anixa Biosciences, last month, announced the initiation of its ovarian cancer CAR-T Phase 1 trial at Moffitt Cancer Center.
- What Anixa Biosciences Does: Anixa Biosciences Inc, a cancer-focused biotechnology company, is engaged in harnessing the body's immune system in the fight against cancer.
- 《贸易》: Anixa生物科学公司纳斯达克(股票代码:ANIX)总裁迈克尔·卡塔拉尼以2.66美元的平均价格收购了总计5,500股票。收购这些股份的成本约为146.3万美元。
- 发生了什么事?:Anixa Biosciences上个月宣布在莫菲特癌症中心启动其卵巢癌CAR-T阶段1试验。
- Anixa生物科学公司做了什么:Anixa Biosciences Inc.是一家专注于癌症的生物技术公司,致力于利用人体免疫系统抗击癌症。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧